Only those tumours with a relatively high activity of OPRT were sensitive to 5'd-FUR. Colon 26, which has a very high rate of pyrimidine nucleoside phosphorylase, showed a relatively high increase in the therapeutic efficacy. It is concluded that a low rate of pyrimidine nucleoside phosphorylase is enough to convert 5'd-FUR to 5-FU; further anabolism of 5-FU catalysed by OPRT may be limiting and explain the differential sensitivity.
Fluoropyrimidines are widely used for the treatment of solid tumours, such as breast, colorectal and head and neck cancer. The prodrug 5'd-FUR (5'-deoxy-5-fluorouridine, Doxifluridine) cannot be converted directly to the nucleotide level due to the presence of a 5-deoxy-ribose moiety and needs to be converted to 5-FU (5-fluorouracil) ( Figure 1 ) for its activation (Armstrong et al., 1980 (Armstrong et al., , 1981 (Armstrong et al., , 1983a Ishitsuka et al., 1980; Hartmann & Matter, 1982) . 5'd-FUR is moderately active in patients (20-30% responders) with various types of tumours (Abele et al., 1984; Alberto et al., 1986 Alberto et al., , 1987 Hurteloup et al., 1986 ) and mice (Armstrong & Diasio, 1980; Bollag & Hartmann, 1980; Ishitsuka et al., 1980; Hartmann & Matter, 1982) . Plasma level of 5-FU are usually 5-20% of those of 5'd-FUR at a molar level and 5-FU mimics 5'd-FUR pharmacokinetics (Sommadossi et 1983; De Bruijn et al., 1985) . In patients peak levels of 5-FU after injection of 15 g 5'd-FUR m-2 were 100-200 gM (Sommadossi et al., 1983; De Bruijn et al., 1985) , which are lower than observed after injection of 500 mg 5-FU m 2 (Kok et al., 1984) . The human xenograft model has a potential unique value in screening and selecting new drugs for clinical trials (Winograd et al., 1987) . We have developed a panel of head and neck cancer xenograft (HNX) tumour lines in order to select compounds for phase II trials with head and neck cancer patients. With drugs such as cisplatin and bleomycin a number of lines responded but with antimetabolites such as methotrexate and 5-FU hardly any activity was found in 14 and 7 lines, respectively (Braakhuis et al., 1983 (Braakhuis et al., , 1988 . Insensitivity to methotrexate was not related to an overproduction of dihydrofolate reductase (Braakhuis et al., 1985) . However, another antimetabolite, 5-aza-2'-deoxycytidine, is active in this model (Braakhuis et al., 1986) . Up to now no biochemical evaluation of HNX cancer lines in relation to sensitivity to fluoropyrimidines has been performed.
Activation of 5'd-FUR to 5-FU may occur selectively in tumour cells compared to normal cells (Armstrong & Diasio, 1981) . The activity of pyrimidine nucleoside phosphorylase appears to be related to the toxicity of 5'd-FUR (Armstrong et al., 1981 (Armstrong et al., , 1983a Hartmann & Matter, 1982; Ishitsuka et al., 1980) but a strict correlation has not been demonstrated (Hartmann & Matter, 1982; Peters et al., 1986a) . Cells with a very low activity of pyrimidine nucleoside phosphorylase showed a low sensitivity to 5'd-FUR, but cell lines with a very high activity were not the most sensitive cell lines. We postulated that although sufficient conversion of 5'd-FUR to 5-FU is essential for a cell to be sensitive to 5'd-FUR, this is not the only critical factor which determines the activity of 5'd-FUR (Peters et al., 1986a) . Further activation of the 5-FU formed from 5'd-FUR appeared to be essential. A cell line in which the direct conversion of 5-FU to FUMP (5-fluorouridine-5'-monophosphate) plays an important role appeared to be very sensitive to 5'd-FUR (Peters et al., 1986a) . In this cell line 5'd-FUR was also able to decrease levels of 5-phosphoribosyl-l-pyrophosphate (PRPP) (Peters et al., 1985) . The other pathways for activation of 5-FU (Figure 1 ) appear to play a less important role in the activity of 5'd-FUR, e.g. the concentration of 2-deoxyribose-lphosphate (dRib-I -P) is negligible under physiological concentrations (Barankiewicz & Henderson, 1977; Peters et al., 1987a) . The role of the various enzymes in drug activation and thus in the relation with antitumour activity of 5-FU and 5'd-FUR can be studied by their measurement with the analogue substrate 5-FU (Peters et al., 1986a The head and neck tumour lines were established from tumours from untreated patients and maintained in female BIO.LP/Cpb nude mice as described previously (Braakhuis et al., 1984) . The murine colon tumours Colon 26 and Colon 38 were maintained in female Balb/c mice and C57B1/6 mice, respectively, as described previously (Peters et al., 1987b) . Histological data of the various tumour lines are summarised in Table I . All mice were obtained from the animal breeding station 'Centraal Proefdieren Bedrijf-TNO' (Zeist, The Netherlands). Tumours were passaged by implanting small fragments (1-5 mm3) in the thoracic region of female mice (about 8 weeks of age; about 20 g). Tumour volume was determined by caliper measurement (length x width x height x 0.5mm3) twice a week. The volume of the tumour was calculated relative to that on the first day of treatment (day 0). Evaluation of the tumour growth delay was performed as described previously (Braakhuis et al., 1983; Peters et al., 1987b) (Peters et al., 1987b) , drugs were always injected between 4 and 6 p.m. Statistical evaluation was performed using Student's t test for unpaired samples.
Enzyme assays
Tumours (ranging in size between 200 and 2,000 mm3) were obtained from non-treated mice. Mice were killed either by ether anaesthesia or by cervical dislocation, which did not affect enzyme activities. Tumours were removed immediately, directly frozen in liquid nitrogen, and stored in either liquid nitrogen or at -800C. Frozen tissues were pulverised using a micro-dismembrator as described (Peters et al., 1986b) , allowing an excellent extraction of enzyme activities. After pulverisation the powder was weighed and suspended in assay buffer (50 mM EDTA, pH 7.4) at a concentration of 1 g tissue per 4 ml buffer. The suspension was centrifuged at 2,500g (5 min, 4°C); and subsequently the supernatant was centrifuged at 11,000g for 10min. The supernatant was immediately used for determination of enzyme activities. Enzyme assays were performed at 37°C in a water bath. Assays with 5-FU as substrate were performed as described previously for cultured cells and human tumours (Peters et al., 1986a,b) . Products were separated from the substrate 5-FU using thin-layer chromatography . In order to prevent breakdown of newly formed nucleotides by phosphatases we added 15mM 2-glycerol-phosphate to these assays. ATP was present at 2.5mM and dRib-1-P also at 2.5mm final concentration. For measurement of direct conversion of 5-FU to FUMP catalysed by orotate phosphoribosyl transferase (OPRT) the pentose phosphates were substituded by 2mM PRPP; 0.6mM oa,fl-methylene-ADP was present to inhibit 5'-nucleotidases; 200-650 4g protein was present. The reaction was initiated by addition of radiolabelled 5-FU (final concentration 0.27mM 6-14C-5-FU with a specificity activity of 4.5 mCi mmol-1). The phosphorolysis of 5'd-FUR to 5-FU and that of uridine to uracil were measured using a recently developed HPLC assay (Laurensse et al., 1988) . The assay was performed with the 11,000g supernatant. The assay mixture (total final volume 200 I) contained 5-100,ug protein and 40mMKH2PO4. The reaction was initiated by addition of 5'd-FUR (final concentrations 0.25-2 mM) or uridine (final concentration 0.5 mM) and stopped by boiling for 3min followed by chilling on ice. Supernatants were analysed with HPLC (Laurensse et al., 1988) .
Pharmacokinetics
In order to reveal possible differences between 5'd-FUR and 5-FU systemic exposure in nude mice and other mice we determined plasma levels after i.p. administration of FLUOROPYRIMIDINES IN HEAD AND NECK CANCER 329 500 mg kg-1. Sample pretreatment and HPLC procedures were described previously (De Bruijn et al., 1985 
Results

Toxicity
The maximum tolerated dose (MTD) for 5-FU was 50mg kg-1 in nude mice, and 100mg kg-1 for Balb/c and C57BI/6 mice. No toxic deaths were observed. Since mice tolerated 5'd-FUR at a dose which was 8-10 times higher than 5-FU (Bollag & Hartmann, 1980) , we initially used 400mg 5'd-FURkg-' in nude mice and 1,000mgkg-1 in Balb/c and C57Bl/6 mice. However, the dose of 5'd-FUR could be increased 20 times to 1,000 and 2,000mgkg-1 in nude mice and normal mice, respectively, which appeared to be the MTD. The moderate weight loss (5-10%) was comparable to that of 5-FU, and was observed only at the first two of the four courses (Figure 2 ). In non-tumourbearing mice, the weight of the mice returned to initial values and was followed by normal weight increase. In the tumour bearing Balb/c mice weight loss was observed after discontinuation of the treatment, due to cachexia caused by the tumour. No weight loss was observed in tumour bearing Balb/c and C57BI/6 mice with 5'd-FUR at doses dl,O00mgkg-. At a dose of 2,500mgkg-1 three of six Balb/c mice died. In nude mice the low dose of 400mgkg-1 caused no weight loss.
Antitumour activity HNX-DU was resistant to 5-FU at 50mgkg-1 and to 5'd-FUR at 400 and 1,000mg kg -1 (Table II) . HNX-KE showed a slight response to 50mg 5-FU kg-1 and at 400mg 5'd-FUR kg 1, but a significant antitumor activity at 1,000mg 5'd-FUR kg-I (Figure 3) . The HNX-G and HNX-E both showed a slight comparable response to 50mg 5-FU kg-1 and 400mg 5'd-FUR kg-1 (Table II) . In HNX-E a better antitumour activity was observed at 1,000mg 5'd- Colon 38 showed a similar sensitivity to 5'd-FUR at 1,000 mg kg-1; also at lower doses a good response was observed (Table III) . Colon 26 was initially tested at 800 and 1,000mg kg -1. Tumour-growth delay was comparable to 5-FU at 100mg kg-1. However, higher doses of 5'd-FUR could be used without lethal toxicity. At 1,500 and 2,000 mg kg-1 antitumour activity was significantly enhanced compared to the schedules with the lower doses. GDF was comparable to values which were usually only observed with the sensitive Colon 38 (Table III) .
Enzyme activities A relatively high Km was observed for 5'd-FUR in all tumours varying from 0.6 to 2mM (Figure 5 ), while the maximal activity with 5'd-FUR varied considerably (Table  IV) . The highest activity in Colon 26 was about 50 times higher than in the tumours with the lowest activity, HNX-DU and HNX-KE. Uridine phosphorylase, measured at saturating uridine concentrations (Table IV) , had the highest activity in Colon 26 and the lowest in HNX-KE. Results were expressed per mg protein, the relative differences based on wet weight were also comparable. For comparison the protein content of the tumours is given (Table IV) .
Pyrimidine nucleoside phosphorylase with 5-FU as substrate in the reverse direction ( Figure 6 ) was higher with dRib-l-P as co-substrate than with Rib-I-P in all tumours; in the HNX tumours at least 10-fold, but in both colon tumours only 3-fold ( Figure 6 ). With Rib-I -P the highest activity was found in Colon 26 and the lowest in HNX-KE and Colon 38. Among the HNX tumours the highest activity was observed in HNX-E. With dRib-I-P the pattern was different, although the highest activity was still present in Colon 26 and the lowest in Colon 38. However, the activities in the HNX tumours were all higher than in Colon 38 and the difference of HNX-E with Colon 26 was less than with Rib-l-P as co-substrate ( Figure 6) . Km values for phosphorylation of FUR (Greenberg et al., 1977) , so the concentration of FUR was not rate-limiting. estimate of the conversion of 5-FU to the nucleotide will be obtained (Peters et al., 1986a (Ishitsuka et al., 1980; Armstrong et al., 1980 Armstrong et al., , 1983a Hartmann & Matter, 1982) although no strict correlation has been demonstrated (Hartmann & Matter, 1982; Peters et al., 1986a) . (Siegel & Lin, 1986) . In our studies it appeared that the rate of phosphorolysis of 5'd-FUR did not correlate with that of uridine, and the pattern of activity was completely different for both substrates. Actually the activity of pyrimidine nucleoside phosphorylase with 5'd-FUR correlated with that of 5-FU and dRib-1-P as substrates. This conversion of 5-FU to FUdR and the cleavage of FUdR are mainly catalysed by a thymidine and/or a uridine-deoxyuridine phosphorylase (Woodman et al., 1980; Peters et al., 1986a) . Enzyme kinetics of pyrimidine nucleoside phosphorylase with 5'd-FUR as a substrate were comparable to other studies, about mM (Armstrong & Diasio, 1980; Choong & Lee, 1986; Miwa et al., 1981) , which is much higher than that for uridine (Leyva et al., 1983; Laurensse et al., 1988) or thymidine (Wataya & Santi, 1981) . So, 5'd-FUR has a low affinity for pyrimidine phosphorylases and might be a substrate for various phosphorylases (Woodman et al., 1980; Choong & Lee, 1986) .
Resistance of the HNX lines to 5-FU might be related to several factors, such as a deficient activation of 5-FU, differences in the inhibition of the target enzyme thymidylate synthase, high intratumoral levels of thymidine or deoxyuridine or the incorporation of 5-FU into RNA . However, the mechanism of 5'd-FUR cytotoxicity is directly analogous to that for 5-FU, inhibition of thymidylate synthase being the most potent mechanism (Armstrong et al., 1983b) . Thus differences between effects of 5-FU and 5'd-FUR are most likely related to activation of 5'd-FUR to 5-FU and subsequently to active nucleotides.
In this panel of tumours uridine phosphorylase appears not be be related to the sensitivity of the tumours to 5'd- phosphorylation to nucleotides and incorporationi into RNA (Armstrong et al., 1983a) . Cory & Cartcr (1982) demonstrcated that 5-FU and 5'd-FUR are not activated in the same way in order to show growth-inhibition. Activation to FdUMP via FUdR is unlikely because of low endogenous levels of the co-substrate dRib-I-P. Levels of Rib-l-P are usually high enough for activation of 5-FU to FUMP via FUR, but this pathway was low in the 5'd-FUR sensitive Colon 38, high in the 5'd-FUR resistant HNX-DU, and very high in Colon 26, and might only be important for Colon 26. However, this way of phosphorylation of 5-FU formed from 5'd-FUR is unlikely (Peters et al., 1986a,) , which could be partially due to: (a) the presence of the modified pentose phosphate 5-deoxy-ribose-1-phosphate which might compete with the substrate Rib-I-P and (b) an interference of 5'd-FUR itself with pyrimidine nucleoside phosphorylase. The only alternative for phosphorylation of 5-FU will be direct conversion to FUMP. The substrate for this reaction, PRPP, could be decreased by 5'd-FUR only in WiDr cells, the most sensitive cell line in this panel (Peters et alt., 1985 (Peters et alt., , 1986a . WiDr cells had a relatively high activity of OPRT both with the analogue substrate 5-FU and the natural substrate orotic acid (Peters et al., 1985 . In the present panel the most sensitive lines Colon 26, Colon 38 and HNX-KE have a relatively high activity of OPRT with 5-FU. So, only tumours with a sufficient capacity to convert 5'd-FUR to 5-FU and a subsequent effective conversion of 5-FU to nucleotides may be sensitive to 5'd-FUR.
Differences between in iio drug handling of different mouse strains have not been observed and therefore extratumoral exposure is considered to be comparable. Thus. differences between 5'd-FUR effects on tumours in nude and normal mice cannot be explained by differences in extratumoral drug handling.
5--FU resistant tumours may not use efficiently the pathway catalysed by OPRT for 5-FU activation, possibly due to a low availability of PRPP or a high activity of pyrimidine nucleoside phosphorylase. Thus inhibition of pyrimidine nucleoside phosphorylase may lead to ac more efficient use of the OPRT pathway, and therapy of 5-FU resistant tumours, such as several head and neck and colon cancers, might be improved by an efficient use of the OPRT pathway. Biochemical modulators, such as inhibitors of uridine phosphorylase may prove to be potential chemotherapeutic agents (Siegel & Lin, 1986) .
Several human colon tumours have a relatively high activity of OPRT compared to adjacent normal mucosal tissue (Peters et atl., 1986b) . So, colorectal cancer might be an attractive tumour type to be treated with 5'd-FUR, and recent results showed an improved therapeutic effect in rectosigmoid colorectal cancer (Abele et al., 1988 ). An advantage over 5-FU might be expected since the 5-FU sensitive tumours will also respond to 5'd-FUR while some 5-FU resistant or relatively resistant tumours might show a better response. Other schedules or ways of administration might be explored to circumvent the observed neurotoxicity.
In conclusion, a better therapeutic efficacy was achieved with 5'd-FUR for several lines than with 5-FU. The enhanced sensitivity to 5'd-FUR might not strictly be related to its rate of conversion to 5-FU. Although a certain amount of activity is essential to convert 5'd-FUR to 5-FU, further metabolism to nucleotides might be limiting. This might lead to an improved therapeutic efficacy of 5'd-FUR compared to 5-FU in tumours with a high OPRT activity such as HNX-KE and Colon 26. These findings indicate that lurther studies aiming at enhancing of therapeutic efficacy observed with 5'd-FUR are warranted.
